Let these three fuel your 2022 gains

Here are your three top U.S. stock picks for 2022—one each from our Conservative, Aggressive and Income portfolios.
In light of ongoing COVID-19 uncertainty, this year we are zeroing in on resilient stocks that have successfully adapted to the pandemic to thrive. That experience will help… Read More

Spinoff spotlight

GLAXOSMITHKLINE PLC ADRs $46 is a spinoff buy. The company (New York symbol GSK; Manufacturing sector; ADRs outstanding: 2.7 billion; Market cap: $124.2 billion; Dividend yield: 4.7%; Takeover Target Rating: Medium; www.gsk.com) is a U.K.-based global healthcare firm that develops and sells products in three main markets: pharmaceuticals (50%… Read More

Latest pharma spinoff should pay off

Johnson & Johnson recently announced that it would spin off its consumer drug business as a separate firm. This follows several other big pharmaceutical firms, including Pfizer, GlaxoSmithKline and Merck, that have completed similar spinoffs.
The breakup will let Johnson & Johnson focus on its more-profitable… Read More